Condition: Breast Cancer · Sponsor: TransThera Sciences (Nanjing), Inc.
The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are: 1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants? 2. What medical problems do participants have when taking the combination therapy? Participants will: Take tinengotinib and fulvestrant to find the optimal dose of tinengotinib for the combination therapy in Part A. In Part B, will take tinengotinib at the optimal dose with fulvestrant or tinengotinib alone to see if the combination therapy works better than tinengotinib monotherapy.
This description comes directly from the study's public registry record.
Caixia Sun · 025-58216298 · sun_caixia@transtherabio.com
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| Linyi Cancer Hospital | Linyi, Shandong, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Not Yet Recruiting |
| The First Medical Center, Chinese PLA General Hospital | Beijing, China | Not Yet Recruiting |
| Southwest Hospital | Chongqing, China | Not Yet Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07498478